| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -26.3 | -22.4 |
| Net income | -26.4 | -22.5 |
| EPS (diluted, $ a share) | $-0.49 | $-9.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SPTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Seaport Therapeutics, Inc.: key numbers
- Share price
- $19.12Close, Nov 16
- Market cap
- $1.02B
- Shares outstanding
- 53.53MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Seaport Therapeutics, Inc.
All →Seaport Therapeutics Director Denice Torres Buys $99.3K of Stock
Denice Torres, Director, bought 5,000 shares of Seaport Therapeutics, Inc. at $19.86 a share, worth $99.3K in total on Nov 3, 2026. Shares held after the trade: 5,000.
- Value
- $99.3K
- Shares
- 5,000
- Price
- $19.86
- Role
- Director
- Trade date
- Nov 3, 2026
Seaport Therapeutics Financial Results
Seaport Therapeutics reported third quarter 2026 financial results, ending the period with $403.8 million in cash and investments. The company highlighted clinical progress, including the dosing of the first patient in a Phase 2a trial for GlyphAgo and positive Phase 1 driving simulation data for GlyphAllo. Management expects current capital to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.
“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts. There are a billion people living with mental illness – waiting and hoping for better medicines. We are committed to our mission to bring better days to patients and their families.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics